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Abstract
It is 35 years since the first description of arrhythmogenic right ventricular cardiomyopathy 
(ARVC) and more than 20 years since the first reports establishing desmosomal gene mutations as 
a major cause of the disease. Early advances in the understanding of the clinical, pathological and 
genetic architecture of ARVC resulted in consensus diagnostic criteria, which proved to be 
sensitive but not entirely specific for the disease. In more recent years, clinical and genetic data 
from families and the recognition of a much broader spectrum of structural disorders affecting 
both ventricles and associated with a propensity to ventricular arrhythmia have raised many 
questions about pathogenesis, disease terminology and clinical management. In this paper, we 
present the conclusions of an expert round table that aimed to summarise the current state of the 
art in arrhythmogenic cardiomyopathies and to define future research priorities.
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Introduction
In recent years, the clinical paradigm of arrhythmogenic right ventricular cardiomyopathy 
(ARVC) has moved on from a focus on severe right ventricular disease and malignant 
arrhythmia to a broader disease spectrum that includes concealed or subclinical phenotypes 
and biventricular disease. This has led to the development of a new concept–arrhythmogenic 
cardiomyopathy (AC) – that embraces a confusing array of disease terms and quite different 
pathologies. In November 2017, a group of international experts met in Athens, Greece, to 
discuss current knowledge about ACs with the aim of defining future research priorities. The 
meeting format was that of a moderated round table discussion (edited highlights of which 
can be viewed at http://www.fondazione-menarini.it/Home/Eventi/International-Closed-
Workshop-on-ArrhythmogenicCardiomyopathy/Presentazione). This document summarizes 
the content of the meeting. A brief summary of each section is presented in Table 1.
What is arrhythmogenic cardiomyopathy?
The term ‘arrhythmogenic cardiomyopathy’ is used to describe a family of diseases that 
feature structural myocardial abnormalities (identified by macroand microscopic 
pathological examination besides cardiac imaging) and ventricular arrhythmia. In Figure 1, 
we show how the most commonly used terms in the literature (including ARVC) can be 
organised by the patterns of ventricular involvement within the rubric of AC.1–3 Inclusion of 
entities such as hypertrophic and restrictive cardiomyopathy is not considered appropriate as 
their aetiology and management rarely overlap with the conceptual model of AC as 
conceived in this paper.
Accepting that a precise definition for AC has yet to be agreed upon, its diagnosis should 
follow a systematic approach that builds on the existing ARVC concept. Fundamental 
aspects include the following:
i. Arrhythmia: frequent ventricular ectopy, from either ventricle, sustained or non-
sustained ventricular tachycardia, or unexplained cardiac arrest are essential 
manifestations of the AC phenotype.
ii. Electrical abnormalities: in addition to the classical ECG changes of ARVC, 
other abnormalities such as conduction disease, atrial arrhythmia, small voltage 
complexes and the pattern of left ventricular disease provide diagnostic clues to 
specific aetiologies.
iii. Structural abnormalities: abnormalities of myocardial structure and dysfunction 
on non-invasive imaging are important but not essential criteria for AC, whereas 
tissue characterisation with cardiac magnetic resonance imaging, and if 
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necessary nuclear imaging and cardiac histopathology, is essential for the 
definition of sub-phenotypes.
iv. Heritability: family history (including clinical evaluation of first-degree relatives 
and at least a three-generation pedigree) is one of the principal diagnostic tools in 
AC. Genetic analysis is central to the diagnosis in probands and defines carrier 
status in relatives. Family history of other relevant traits such as premature 
conduction disease or extra-cardiac manifestations (skin, hair and neuromuscular 
phenotypes) helps to orient and interpret diagnostic tests.
v. Phenocopy exclusion: in all cases of AC, it is important to exclude mimics of the 
AC phenotype such as congenital anomalies, pulmonary hypertension, cardiac 
sarcoidosis and myocarditis.
What is the genetic architecture of arrhythmogenic cardiomyopathy?
Pathogenic mutations in desmosomal genes (JUP, DSP, PKP2, DSG2, DSC2) account for 
disease in over 50% of patients with classical ARVC.4–9 Non-desmosomal pathogenic 
variants are described in DES, LMNA, SCN5A, CDH2, CTNNA3, FLNC, PLN, TGFB3, 
TMEM43, RYR2, TJP1 and TTN10–21 and reports describe a disproportionately high burden 
of ventricular arrhythmia in dilated cardiomyopathy caused by pathogenic variants in 
RBM20, TNNT2, and BAG3.22–24 The possible relation between the main causative genes 
and the relative involvement of the left and right ventricles are shown in Table 
2.4,6,8–16,19,25–31
Despite the prominence given to gene mutations in the Task Force diagnostic criteria for 
ARVC, many pathogenic variants classified as ‘pathogenic’ or ‘likely pathogenic’ are also 
seen in people without AC. In part, this reflects the challenge of accurately classifying 
missense variants due to the limitations of current methods of variant calling (functional 
studies, in-silico methods, etc.). Nevertheless, even within affected families the penetrance 
of most pathogenic desmosome gene variants is relatively low (approximately 30%), 
suggesting that disease expression is influenced by other genetic or environmental factors.32 
For example, endurance athletes with desmosomal variants have earlier disease onset, are 
more likely to meet ARVC Task Force criteria, and have lower lifetime-free survival from 
ventricular tachycardia/fibrillation and heart failure.33
Many questions and challenges remain regarding the genetics of AC. In particular, the 
increasing number of variants identified by continuously evolving genomic methods has 
raised the need for more extensive and better curated controls. There is a growing focus on 
deep intronic variants that alter splicing in genes already known to be associated with the 
disorder and the use of approaches such as RNA sequencing or assessment of long non-
coding RNAs that may improve diagnostic yield. The need for functional assays that can 
provide quantitative assessment of novel variants and their potential role in disease becomes 
ever more pressing.
Elliott et al. Page 3

















































What is the role of the desmosome in arrhythmogenic cardiomyopathy?
Arrhythmogenic cardiomyopathy is associated with mutations in desmosome genes, and 
thus it has been assumed that the inability to effectively withstand mechanical stress is a 
major contributing factor to disease pathogenesis. However, many other functions for 
desmosomes and their components are emerging and may turn out to have role in the 
pathogenesis of AC (Figure 2). Postnatally in vertebrates, an intermingling of desmosome 
and other junction components occurs, creating a specialised form of junctions called ‘area 
compositae’.34 This mixed junction may provide additional strength to the junction by 
distributing intermediate filament connections throughout the junctional interface. For 
instance, desmosomes play critical roles in trafficking and stability of the gap junction 
protein connexin 4335,36 and other membrane channels including Nav 1.5.
37 Thus, impaired 
desmosome function also leads to loss of efficient electrical coupling and conduction that 
could be linked to arrhythmias. Desmosomes also help localize the actin-regulatory 
machinery including Rho-GTPases,38 which might further impact the organisation and 
function of the adherens junctions associated actin cytoskeleton and contractile apparatus. 
Desmosome components also regulate multiple other signalling pathways including 
GSK3beta/Wnt,39,40 p38/TGFbeta41 and Ras/Erk2.42 Coupling with these pathways 
regulates multiple endpoints in skin and heart, including cell fate, differentiation, and 
fibrotic gene expression.
The first genetic studies of AC arose from the study of autosomal recessive AC syndromes 
associated with a skin disease (palmoplantar keratoderma) and woolly hair.4,5,42,43 Better 
understanding of desmosomal function and disease mechanisms in the skin from AC patients 
may provide insights into AC pathogenesis and potential therapeutic strategies. Further 
insights come from studying molecules that regulate desmosomes including the iRhom2/
ADAM17 pathway that cleaves membrane bound cytokines, growth factors and desmoglein 
2.44–47 Also, there is emerging evidence of links between systemic inflammatory stress and 
perturbed desmosome function in both heart and skin.48
What is the role of inflammation in the pathogenesis of arrhythmogenic 
cardiomyopathy?
Evidence from autopsy and endomyocardial biopsy in classic ARVC suggests that cell death 
is largely the result of apoptosis.49,50 The adipocytes seen on histology appear not to result 
from cardiomyocyte transdifferentiation,51–54 but are instead derived from interstitial 
mesenchymal fibroblasts. Cardiomyocyte loss is usually patchy, but can rarely occur as acute 
segmental pathology with clinical manifestations of angina, ECG ST-segment elevation and 
release of troponin mimicking myocardial infarction.54
Autopsy studies show that myocardial inflammation in the form of T-cell infiltrates is 
present in approximately two-thirds of ARVC cases53,55 (Figure 3); the absence of 
neutrophils rules out ischaemic injury. The search for cardiotropic viruses in the 
myocardium has yielded conflicting results56,57 with adenovirus, cytomegalovirus, hepatitis 
C virus, parvovirus and even enterovirus present in some specimens. Whether viruses are 
by-standers or true pathogenetic viral particles remains an unsolved issue.
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Immunohistochemistry has shown a reduced signal for plakoglobin at the intercalated disc,58 
but other studies indicate that a reduced desmosomal protein signal is found also in patients 
with giant cell myocarditis and sarcoidosis.59 The latter is a peculiar form of chronic 
myocarditis that can mimic AC.60
It remains unclear if myocarditis in AC is a primary phenomenon or reactive to spontaneous 
cardiomyocyte death. The hypothesis that a genetically61 vulnerable myocardium may 
predispose to myocarditis has been advanced62 and local myocardial production of selected 
cytokines and alterations in the balance between circulating pro-inflammatory and anti-
inflammatory cytokines in patients with AC has been demonstrated.59 In one study, 
cytokines implicated in granulomatous inflammation promoted rapid intracellular 
translocation of junctional plakoglobin in cultured neonatal rat ventricular myocytes, 
suggesting that inflammatory mediators might play a role in AC, even in the absence of 
infiltrating inflammatory cells.59 Furthermore, the increasing understanding of the interplay 
between immune response and exercise might provide further insights in the mechanisms of 
exercise promoted disease progression in AC.61
How can sudden cardiac death prediction be improved in arrhythmogenic 
cardiomyopathy?
Most evidence suggests that in AC caused by desmosomal mutations, the degree of 
structural remodelling is a key determinant of ventricular arrhythmia. Data on arrhythmia 
risk in non-desmosomal forms of AC are still emerging, but there are already compelling 
findings for some genetic subtypes. For example, registry data in AC caused by LMNA 
mutations suggest that male sex, non-sustained ventricular tachycardia, reduced ejection 
fraction and non-missense mutations define the patient at risk of ventricular tachycardia/
fibrillation.63 Other genetic causes of AC are less well studied, but data suggest that for 
mutations in TMEM43, RBM20, the founder R14del in phospholamban and FLNC, sudden 
death risk relates to the severity of structural and functional abnormalities, although 
anecdotal reports and familial evaluation suggest that sudden death can be the initial 
presenting feature.16,30 Several novel disease biomarkers that might aid risk prediction are 
under study, such as testosterone, BIN-1, soluble ST2 and anti-desmoglein-2 autoantibodies.
64–67 However, these have not been compared with conventional risk factors. The dynamic 
nature of the disease and inflammatory hot phases may promote a temporary increased 
vulnerability to ventricular fibrillation. Anti-inflammatory agents may provide a means for 
reducing arrhythmic risk but require sensitive and specific biomarkers of disease activity and 
therapeutic response.
The diversity of causes for AC, together with phenotypic variability and age-related 
penetrance of genetic mutations, means that risk assessment needs to be tailored to aetiology 
and stage of disease (Figure 4). For patients fulfilling current Task Force criteria for ARVC, 
high- and low-risk cohorts have been identified, but there are many individuals who fall into 
an intermediate category for whom clear guidance on management is lacking. Moreover, 
most approaches to risk estimation are based on a relatively crude assessment of relative risk 
rather than absolute risk prediction. The challenge of optimal risk modelling might be 
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addressed through the integration of large deeply phenotyped and genotyped cohorts with 
sufficient follow-up to permit development and validation of risk models that integrate 
genetic, ECG, electrophysiological and imaging data.
What are the prospects for trials in arrhythmogenic cardiomyopathy?
Prospective treatment trials focused on novel therapeutic approaches for the treatment of AC 
are lacking. This reflects the challenges for conventional trial design in diseases that are rare, 
heterogeneous in presentation, associated with prominent arrhythmia, and slowly 
progressive. Hard endpoints such as mortality are difficult to achieve in uncommon disorders 
with long natural histories. Therefore, it is of utmost importance to define subsets of patients 
with a sufficiently high likelihood of meeting clinically meaningful surrogate endpoints 
within the duration of a trial, for example progression of structural or electrical 
characteristics. The endpoint for trials targeting cardiac arrhythmias might include time to 
the first episode of sustained ventricular tachycardia/fibrillation or premature ventricular 
complex frequency, as these appear to predict the risk of sustained ventricular arrhythmias. 
Trials targeting heart failure endpoints are challenging due to slow and variable disease 
progression.68,69 Serial evaluation of structural myocardial abnormalities is difficult due to 
the limitations of conventional echocardiography in assessing the right ventricle and because 
the presence of an implantable cardioverter-defibrillator in many patients precludes serial 
magnetic resonance imaging. For these reasons, it is likely that trials in this area will require 
other biomarkers of ventricular impairment and remodelling such as natriuretic peptides and 
circulating markers of fibrosis.
Specific interventions that have potential to reduce life-threatening ventricular arrhythmias 
include pharmacologic agents such as beta-blockers, class 1 and 3 anti-arrhythmic agents 
such as flecainide, sotalol, tikosyn and amiodarone, endocardial and/or epicardial catheter 
ablation, and sympathetic denervation. As vigorous exercise seems to be factor for disease 
progression in ARVC and possibly in other forms of AC such as laminopathy,70–73 clinical 
trials to determine whether exercise restriction can prevent development of ARVC are 
warranted.
Pharmacologic agents that could directly target the underlying disease mechanism in the 
various forms of AC are under investigation. For example, a small molecule inhibitor of 
GSK3β, a major regulator of Wnt/β-catenin signalling identified in an unbiased chemical 
screen in a zebrafish model of ARVC,74 has been shown to dramatically reduce arrhythmias, 
myocardial damage and exercise-induced injury in mouse models of ARVC.74,75 However, 
effective drug therapy will require chronic administration, and long-term use of Wnt 
agonists may have unacceptable off-target effects, including increased risk of developing 
cancer. Thus, a potential future strategy to develop a truly mechanism-based drug therapy 
will be to identify pathways and targets downstream of GSK3β that are driving the 
cardiomyopathic disease phenotype.
In animal studies, loss of functional lamin proteins produces strong cellular stress signals 
that activate the p38 mitogen-activated protein kinase (MAPK) pathway which in turn 
causes decreased contractility, cardiomyocyte apoptosis, cardiomyocyte hypertrophy, and 
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increased brain natriuretic peptide expression.76 ARRY-797 is an oral administered selective 
p38 MAPK inhibitor that reverses cardiac dysfunction in an animal model of LMNA and 
studies are now underway in patients with dilated cardiomyopathy caused by LMNA 
mutations (ClinicalTrials.gov Identifier: ).
Conclusions
Since the first detailed clinical description of ARVC, dramatic advances have been made 
regarding its pathogenesis, diagnosis and management. This progress was made possible by 
the development of single centre registries working alone or in partnership and also by the 
efforts of dedicated basic research laboratories. With the recognition of AC as a broad 
spectrum of disease, the need for national and international collaborative efforts is even 
greater. We hope this document will contribute to this endeavour.
Funding
This project was an independent initiative supported by the Fondazione Internazionale Menarini, which had no part 
in designing or approving the agenda. St. Bartholomew’s Hospital, the Amsterdam UMC and the Department of 
Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua-Azienda Ospedaliera are members of 
ERN GUARD-HEART (European Reference Network for Rare and Complex Diseases of the Heart; http://
guardheart.ern-net.eu), which endorsed the meeting.
Conflict of interest: H.C. reports grants and personal fees from Boston Scientifiic, and personal fees from 
Medtronic, St Jude Medical, during the conduct of the study. D.P.J. reports grants from Menarini Foundation, 
during the conduct of the study; personal fees from Alnylam, GlaxoSmithKline, Pfizer, outside the submitted work. 
H.T. reports personal fees from Abbott, Cooltech, outside the submitted work. All other authors have nothing to 
disclose.
References
1. Zorzi A, Perazzolo Marra M, Rigato I, De Lazzari M, Susana A, Niero A, Pilichou K, Migliore F, 
Rizzo S, Giorgi B, De Conti G, Sarto P, Serratosa L, Patrizi G, De Maria E, Pelliccia A, Basso C, 
Schiavon M, Bauce B, Iliceto S, Thiene G, Corrado D. Nonischemic left ventricular scar as a 
substrate of life-threatening ventricular arrhythmias and sudden cardiac death in competitive 
athletes. Circ Arrhythm Electrophysiol 2016;9:e004229. [PubMed: 27390211] 
2. Nucifora G, Muser D, Masci PG, Barison A, Rebellato L, Piccoli G, Daleffe E, Toniolo M, Zanuttini 
D, Facchin D, Lombardi M, Proclemer A. Prevalence and prognostic value of concealed structural 
abnormalities in patients with apparently idiopathic ventricular arrhythmias of left versus right 
ventricular origin: a magnetic resonance imaging study. Circ Arrhythm Electrophysiol 2014;7:456–
462. [PubMed: 24771543] 
3. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Bohm M, Duboc D, Gimeno J, de 
Groote P, Imazio M, Heymans S, Klingel K, Komajda M, Limongelli G, Linhart A, Mogensen J, 
Moon J, Pieper PG, Seferovic PM, Schueler S, Zamorano JL, Caforio AL, Charron P. Proposal for a 
revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its 
implications for clinical practice: a position statement of the ESC working group on myocardial and 
pericardial diseases. Eur Heart J 2016;37:1850–1858. [PubMed: 26792875] 
4. McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, Norman M, 
Baboonian C, Jeffery S, McKenna WJ. Identification of a deletion in plakoglobin in arrhythmogenic 
right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). 
Lancet 2000;355:2119–2124. [PubMed: 10902626] 
5. Norgett EE, Hatsell SJ, Carvajal-Huerta L, Cabezas JC, Common J, Purkis PE, Whittock N, Leigh 
IM, Stevens HP, Kelsell DP. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate 
filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol 
Genet 2000;9:2761–2766. [PubMed: 11063735] 
Elliott et al. Page 7

















































6. Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, Lerman BB, Markowitz SM, 
Ellinor PT, MacRae CA, Peters S, Grossmann KS, Drenckhahn J, Michely B, Sasse-Klaassen S, 
Birchmeier W, Dietz R, Breithardt G, Schulze-Bahr E, Thierfelder L. Mutations in the desmosomal 
protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 
2004;36:1162–1164. [PubMed: 15489853] 
7. Awad MM, Dalal D, Cho E, Amat-Alarcon N, James C, Tichnell C, Tucker A, Russell SD, Bluemke 
DA, Dietz HC, Calkins H, Judge DP. DSG2 mutations contribute to arrhythmogenic right 
ventricular dysplasia/cardiomyopathy. Am J Hum Genet 2006;79:136–142. [PubMed: 16773573] 
8. Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, Frigo G, Vettori A, Valente M, 
Towbin J, Thiene G, Danieli GA, Rampazzo A. Mutations in desmoglein-2 gene are associated with 
arrhythmogenic right ventricular cardiomyopathy. Circulation 2006;113:1171–1179. [PubMed: 
16505173] 
9. Heuser A, Plovie ER, Ellinor PT, Grossmann KS, Shin JT, Wichter T, Basson CT, Lerman BB, 
Sasse-Klaassen S, Thierfelder L, MacRae CA, Gerull B. Mutant desmocollin-2 causes 
arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2006;79:1081–1088. [PubMed: 
17186466] 
10. van Tintelen JP, Van Gelder IC, Asimaki A, Suurmeijer AJ, Wiesfeld AC, Jongbloed JD, van den 
Wijngaard A, Kuks JB, van Spaendonck-Zwarts KY, Notermans N, Boven L, van den Heuvel F, 
Veenstra-Knol HE, Saffitz JE, Hofstra RM, van den Berg MP. Severe cardiac phenotype with right 
ventricular predominance in a large cohort of patients with a single missense mutation in the DES 
gene. Heart Rhythm 2009;6:1574–1583. [PubMed: 19879535] 
11. Quarta G, Syrris P, Ashworth M, Jenkins S, Zuborne Alapi K, Morgan J, Muir A, Pantazis A, 
McKenna WJ, Elliott PM. Mutations in the lamin A/C gene mimic arrhythmogenic right 
ventricular cardiomyopathy. Eur Heart J 2012;33:1128–1136. [PubMed: 22199124] 
12. Te Riele AS, Agullo-Pascual E, James CA, Leo-Macias A, Cerrone M, Zhang M, Lin X, Lin B, 
Sobreira NL, Amat-Alarcon N, Marsman RF, Murray B, Tichnell C, van der Heijden JF, Dooijes 
D, van Veen TA, Tandri H, Fowler SJ, Hauer RN, Tomaselli G, van den Berg MP, Taylor MR, Brun 
F, Sinagra G, Wilde AA, Mestroni L, Bezzina CR, Calkins H, Peter van Tintelen J, Bu L, Delmar 
M, Judge DP. Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular 
dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. 
Cardiovasc Res 2017;113:102–111. [PubMed: 28069705] 
13. Mayosi BM, Fish M, Shaboodien G, Mastantuono E, Kraus S, Wieland T, Kotta MC, Chin A, 
Laing N, Ntusi NB, Chong M, Horsfall C, Pimstone SN, Gentilini D, Parati G, Strom TM, 
Meitinger T, Pare G, Schwartz PJ, Crotti L. Identification of cadherin 2 (CDH2) mutations in 
arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2017;10:e001605. 
[PubMed: 28280076] 
14. van Hengel J, Calore M, Bauce B, Dazzo E, Mazzotti E, De Bortoli M, Lorenzon A, Li Mura IE, 
Beffagna G, Rigato I, Vleeschouwers M, Tyberghein K, Hulpiau P, van Hamme E, Zaglia T, 
Corrado D, Basso C, Thiene G, Daliento L, Nava A, van Roy F, Rampazzo A. Mutations in the 
area composita protein alphaT-catenin are associated with arrhythmogenic right ventricular 
cardiomyopathy. Eur Heart J 2013;34:201–210. [PubMed: 23136403] 
15. Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V, Padron-Barthe 
L, Duro-Aguado I, Jimenez-Jaimez J, Hidalgo-Olivares VM, Garcia-Campo E, Lanzillo C, Suarez-
Mier MP, Yonath H, Marcos-Alonso S, Ochoa JP, Santome JL, Garcia-Giustiniani D, Rodriguez-
Garrido JL, Dominguez F, Merlo M, Palomino J, Pena ML, Trujillo JP, Martin-Vila A, Stolfo D, 
Molina P, Lara-Pezzi E, Calvo-Iglesias FE, Nof E, Calo L, Barriales-Villa R, Gimeno-Blanes JR, 
Arad M, Garcia-Pavia P, Monserrat L. Truncating FLNC mutations are associated with high-risk 
dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol 2016;68:2440–2451. [PubMed: 
27908349] 
16. van der Zwaag PA, van Rijsingen IA, Asimaki A, Jongbloed JD, van Veldhuisen DJ, Wiesfeld AC, 
Cox MG, van Lochem LT, de Boer RA, Hofstra RM, Christiaans I, van Spaendonck-Zwarts KY, 
Lekanne dit Deprez RH, Judge DP, Calkins H, Suurmeijer AJ, Hauer RN, Saffitz JE, Wilde AA, 
van den Berg MP, van Tintelen JP. Phospholamban R14del mutation in patients diagnosed with 
dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting 
the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail 2012;14:1199–1207. [PubMed: 
22820313] 
Elliott et al. Page 8

















































17. Beffagna G, Occhi G, Nava A, Vitiello L, Ditadi A, Basso C, Bauce B, Carraro G, Thiene G, 
Towbin JA, Danieli GA, Rampazzo A. Regulatory mutations in transforming growth factor-beta3 
gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res 2005;65:366–
373. [PubMed: 15639475] 
18. Haywood AF, Merner ND, Hodgkinson KA, Houston J, Syrris P, Booth V, Connors S, Pantazis A, 
Quarta G, Elliott P, McKenna W, Young TL. Recurrent missense mutations in TMEM43 (ARVD5) 
due to founder effects cause arrhythmogenic cardiomyopathies in the UK and Canada. Eur Heart J 
2013;34:1002–1011. [PubMed: 23161701] 
19. Taylor M, Graw S, Sinagra G, Barnes C, Slavov D, Brun F, Pinamonti B, Salcedo EE, Sauer W, 
Pyxaras S, Anderson B, Simon B, Bogomolovas J, Labeit S, Granzier H, Mestroni L. Genetic 
variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. 
Circulation 2011;124:876–885. [PubMed: 21810661] 
20. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G, Brahmbhatt B, 
Brown K, Bauce B, Muriago M, Basso C, Thiene G, Danieli GA, Rampazzo A. Identification of 
mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right 
ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001;10:189–194. [PubMed: 
11159936] 
21. De Bortoli M, Postma AV, Poloni G, Calore M, Minervini G, Mazzotti E, Rigato I, Ebert M, 
Lorenzon A, Vazza G, Cipriani A, Bariani R, Perazzolo Marra M, Husser D, Thiene G, Daliento L, 
Corrado D, Basso C, Tosatto SCE, Bauce B, van Tintelen JP, Rampazzo A. Whole-exome 
sequencing identifies pathogenic variants in TJP1 gene associated with arrhythmogenic 
cardiomyopathy. Circ Genom Precis Med 2018;11:e002123. [PubMed: 30354300] 
22. van den Hoogenhof MM, Beqqali A, Amin AS, van der Made I, Aufiero S, Khan MA, Schumacher 
CA, Jansweijer JA, van Spaendonck-Zwarts KY, Remme CA, Backs J, Verkerk AO, Baartscheer 
A, Pinto YM, Creemers EE. RBM20 mutations induce an arrhythmogenic dilated cardiomyopathy 
related to disturbed calcium handling. Circulation 2018;138:1330–1342. [PubMed: 29650543] 
23. Fiset C, Giles WR. Cardiac troponin T mutations promote life-threatening arrhythmias. J Clin 
Invest 2008;118:3845–3847. [PubMed: 19033655] 
24. Feldman AM, Gordon J, Wang J, Song J, Zhang XQ, Myers VD, Tilley DG, Gao E, Hoffman NE, 
Tomar D, Madesh M, Rabinowitz J, Koch WJ, Su F, Khalili K, Cheung JY. BAG3 regulates 
contractility and Ca2+ homeostasis in adult mouse ventricular myocytes. J Mol Cell Cardiol 
2016;92:10–20. [PubMed: 26796036] 
25. Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, Rossi V, Zimbello R, Simionati B, 
Basso C, Thiene G, Towbin JA, Danieli GA. Mutation in human desmoplakin domain binding to 
plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J 
Hum Genet 2002;71:1200–1206. [PubMed: 12373648] 
26. Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JD, Murray B, te Riele 
AS, van den Berg MP, Bikker H, Atsma DE, de Groot NM, Houweling AC, van der Heijden JF, 
Russell SD, Doevendans PA, van Veen TA, Tandri H, Wilde AA, Judge DP, van Tintelen JP, 
Calkins H, Hauer RN. Impact of genotype on clinical course in arrhythmogenic right ventricular 
dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J 2015;36:847–855. [PubMed: 
25616645] 
27. Rampazzo A, Nava A, Danieli GA, Buja G, Daliento L, Fasoli G, Scognamiglio R, Corrado D, 
Thiene G. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 
14q23-q24. Hum Mol Genet 1994;3:959–962. [PubMed: 7951245] 
28. Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM, Drenckhahn JD, Kupprion C, 
Ramadanova K, Thierfelder L, McKenna W, Gallagher B, Morris-Larkin L, Bassett AS, Parfrey 
PS, Young TL. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal 
arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 
2008;82:809–821. [PubMed: 18313022] 
29. Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, Feng Z, Muller S, Kayvanpour E, Vogel 
B, Sedaghat-Hamedani F, Lim WK, Zhao X, Fradkin D, Kohler D, Fischer S, Franke J, Marquart 
S, Barb I, Li DT, Amr A, Ehlermann P, Mereles D, Weis T, Hassel S, Kremer A, King V, Wirsz E, 
Isnard R, Komajda M, Serio A, Grasso M, Syrris P, Wicks E, Plagnol V, Lopes L, Gadgaard T, 
Eiskjaer H, Jorgensen M, Garcia-Giustiniani D, Ortiz-Genga M, Crespo-Leiro MG, Deprez RH, 
Elliott et al. Page 9

















































Christiaans I, van Rijsingen IA, Wilde AA, Waldenstrom A, Bolognesi M, Bellazzi R, Morner S, 
Bermejo JL, Monserrat L, Villard E, Mogensen J, Pinto YM, Charron P, Elliott P, Arbustini E, 
Katus HA, Meder B. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 
2015;36:1123–1135a. [PubMed: 25163546] 
30. Refaat MM, Lubitz SA, Makino S, Islam Z, Frangiskakis JM, Mehdi H, Gutmann R, Zhang ML, 
Bloom HL, MacRae CA, Dudley SC, Shalaby AA, Weiss R, McNamara DM, London B, Ellinor 
PT. Genetic variation in the alternative splicing regulator RBM20 is associated with dilated 
cardiomyopathy. Heart Rhythm 2012;9:390–396. [PubMed: 22004663] 
31. Toro R, Perez-Serra A, Campuzano O, Moncayo-Arlandi J, Allegue C, Iglesias A, Mangas A, 
Brugada R. Familial dilated cardiomyopathy caused by a novel frameshift in the BAG3 gene. 
PLoS One 2016;11:e0158730. [PubMed: 27391596] 
32. Dalal D, James C, Devanagondi R, Tichnell C, Tucker A, Prakasa K, Spevak PJ, Bluemke DA, 
Abraham T, Russell SD, Calkins H, Judge DP. Penetrance of mutations in plakophilin-2 among 
families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 
2006;48:1416–1424. [PubMed: 17010805] 
33. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, Tedford RJ, Judge DP, 
Calkins H. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right 
ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll 
Cardiol 2013;62:1290–1297. [PubMed: 23871885] 
34. Calore M, Lorenzon A, De Bortoli M, Poloni G, Rampazzo A. Arrhythmogenic cardiomyopathy: a 
disease of intercalated discs. Cell Tissue Res 2015;360:491–500. [PubMed: 25344329] 
35. Patel DM, Dubash AD, Kreitzer G, Green KJ. Disease mutations in desmoplakin inhibit Cx43 
membrane targeting mediated by desmoplakin-EB1 interactions. J Cell Biol 2014;206:779–797. 
[PubMed: 25225338] 
36. Kam CY, Dubash AD, Magistrati E, Polo S, Satchell KJF, Sheikh F, Lampe PD, Green KJ. 
Desmoplakin maintains gap junctions by inhibiting Ras/MAPK and lysosomal degradation of 
connexin-43. J Cell Biol 2018;217:3219–3235. [PubMed: 29959233] 
37. Sato PY, Coombs W, Lin X, Nekrasova O, Green KJ, Isom LL, Taffet SM, Delmar M. Interactions 
between ankyrin-G, plakophilin-2, and connexin 43 at the cardiac intercalated disc. Circ Res 
2011;109:193–201. [PubMed: 21617128] 
38. Spindler V, Waschke J. Role of Rho GTPases in desmosomal adhesion and pemphigus 
pathogenesis. Ann Anat 2011;193:177–180. [PubMed: 21441018] 
39. Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, Khoury DS, Marian AJ. 
Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates 
phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest 2006;116:2012–
2021. [PubMed: 16823493] 
40. Giuliodori A, Beffagna G, Marchetto G, Fornetto C, Vanzi F, Toppo S, Facchinello N, Santimaria 
M, Vettori A, Rizzo S, Della Barbera M, Pilichou K, Argenton F, Thiene G, Tiso N, Basso C. Loss 
of cardiac Wnt/beta-catenin signalling in desmoplakin-deficient AC8 zebrafish models is rescuable 
by genetic and pharmacological intervention. Cardiovasc Res 2018;114:1082–1097. [PubMed: 
29522173] 
41. Dubash AD, Kam CY, Aguado BA, Patel DM, Delmar M, Shea LD, Green KJ. Plakophilin-2 loss 
promotes TGF-beta1/p38 MAPK-dependent fibrotic gene expression in cardiomyocytes. J Cell 
Biol 2016;212:425–438. [PubMed: 26858265] 
42. Chen X, Bonne S, Hatzfeld M, van Roy F, Green KJ. Protein binding and functional 
characterization of plakophilin 2. Evidence for its diverse roles in desmosomes and beta -catenin 
signaling. J Biol Chem 2002;277:10512–10522. [PubMed: 11790773] 
43. Maruthappu T, Posafalvi A, Castelletti S, Delaney PJ, Syrris P, O’Toole EA, Green KJ, Elliott PM, 
Lambiase PD, Tinker A, McKenna WJ, Kelsell DP. Loss of function desmoplakin I and II 
mutations underlie dominant arrhythmogenic cardiomyopathy with a hair and skin phenotype. Br J 
Dermatol 2019;180:1114–1122. [PubMed: 30382575] 
44. Brooke MA, Etheridge SL, Kaplan N, Simpson C, O’Toole EA, Ishida-Yamamoto A, Marches O, 
Getsios S, Kelsell DP. iRHOM2-dependent regulation of ADAM17 in cutaneous disease and 
epidermal barrier function. Hum Mol Genet 2014;23:4064–4076. [PubMed: 24643277] 
Elliott et al. Page 10

















































45. Blaydon DC, Biancheri P, Di WL, Plagnol V, Cabral RM, Brooke MA, van Heel DA, Ruschendorf 
F, Toynbee M, Walne A, O’Toole EA, Martin JE, Lindley K, Vulliamy T, Abrams DJ, MacDonald 
TT, Harper JI, Kelsell DP. Inflammatory skin and bowel disease linked to ADAM17 deletion. N 
Engl J Med 2011;365: 1502–1508. [PubMed: 22010916] 
46. Maruthappu T, Chikh A, Fell B, Delaney PJ, Brooke MA, Levet C, Moncada-Pazos A, Ishida-
Yamamoto A, Blaydon D, Waseem A, Leigh IM, Freeman M, Kelsell DP. Rhomboid family 
member 2 regulates cytoskeletal stress-associated keratin 16. Nat Commun 2017;8:14174. 
[PubMed: 28128203] 
47. Samuelov L, Sarig O, Harmon RM, Rapaport D, Ishida-Yamamoto A, Isakov O, Koetsier JL, Gat 
A, Goldberg I, Bergman R, Spiegel R, Eytan O, Geller S, Peleg S, Shomron N, Goh CS, Wilson 
NJ, Smith FJ, Pohler E, Simpson MA, McLean WH, Irvine AD, Horowitz M, McGrath JA, Green 
KJ, Sprecher E. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and 
metabolic wasting. Nat Genet 2013;45:1244–1248. [PubMed: 23974871] 
48. Paller AS, Czarnowicki T, Renert-Yuval Y, Holland K, Huynh T, Sadlier M, McAleer MA, Tran G, 
Geddes GC, Irvine AD, Guttman-Yassky E. The spectrum of manifestations in desmoplakin gene 
(DSP) spectrin repeat 6 domain mutations: immunophenotyping and response to ustekinumab. J 
Am Acad Dermatol 2018;78:498–505.e2. [PubMed: 29066275] 
49. Mallat Z, Tedgui A, Fontaliran F, Frank R, Durigon M, Fontaine G. Evidence of apoptosis in 
arrhythmogenic right ventricular dysplasia. N Engl J Med 1996;335:1190–1196. [PubMed: 
8815941] 
50. Valente M, Calabrese F, Thiene G, Angelini A, Basso C, Nava A, Rossi L. In vivo evidence of 
apoptosis in arrhythmogenic right ventricular cardiomyopathy. Am J Pathol 1998;152:479–484. 
[PubMed: 9466574] 
51. d’Amati G, di Gioia CR, Giordano C, Gallo P. Myocyte transdifferentiation: a possible 
pathogenetic mechanism for arrhythmogenic right ventricular cardiomyopathy. Arch Pathol Lab 
Med 2000;124:287–290. [PubMed: 10656741] 
52. Pilichou K, Remme CA, Basso C, Campian ME, Rizzo S, Barnett P, Scicluna BP, Bauce B, van 
den Hoff MJ, de Bakker JM, Tan HL, Valente M, Nava A, Wilde AA, Moorman AF, Thiene G, 
Bezzina CR. Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related 
arrhythmogenic right ventricular cardiomyopathy. J Exp Med 2009;206:1787–1802. [PubMed: 
19635863] 
53. Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular 
cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation 1996;94:983–991. [PubMed: 
8790036] 
54. Bauce B, Basso C, Rampazzo A, Beffagna G, Daliento L, Frigo G, Malacrida S, Settimo L, Danieli 
G, Thiene G, Nava A. Clinical profile of four families with arrhythmogenic right ventricular 
cardiomyopathy caused by dominant desmoplakin mutations. Eur Heart J 2005;26:1666–1675. 
[PubMed: 15941723] 
55. Thiene G, Corrado D, Nava A, Rossi L, Poletti A, Boffa GM, Daliento L, Pennelli N. Right 
ventricular cardiomyopathy: is there evidence of an inflammatory aetiology? Eur Heart J 1991;12 
Suppl D:22–25.
56. Bowles NE, Ni J, Marcus F, Towbin JA. The detection of cardiotropic viruses in the myocardium 
of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 
2002;39:892–895. [PubMed: 11869858] 
57. Calabrese F, Basso C, Carturan E, Valente M, Thiene G. Arrhythmogenic right ventricular 
cardiomyopathy/dysplasia: is there a role for viruses? Cardiovasc Pathol 2006;15:11–17. 
[PubMed: 16414451] 
58. Asimaki A, Tandri H, Huang H, Halushka MK, Gautam S, Basso C, Thiene G, Tsatsopoulou A, 
Protonotarios N, McKenna WJ, Calkins H, Saffitz JE. A new diagnostic test for arrhythmogenic 
right ventricular cardiomyopathy. N Engl J Med 2009;360:1075–1084. [PubMed: 19279339] 
59. Asimaki A, Tandri H, Duffy ER, Winterfield JR, Mackey-Bojack S, Picken MM, Cooper LT, 
Wilber DJ, Marcus FI, Basso C, Thiene G, Tsatsopoulou A, Protonotarios N, Stevenson WG, 
McKenna WJ, Gautam S, Remick DG, Calkins H, Saffitz JE. Altered desmosomal proteins in 
granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular 
cardiomyopathy. Circ Arrhythm Electrophysiol 2011;4:743–752. [PubMed: 21859801] 
Elliott et al. Page 11

















































60. Vasaiwala SC, Finn C, Delpriore J, Leya F, Gagermeier J, Akar JG, Santucci P, Dajani K, Bova D, 
Picken MM, Basso C, Marcus F, Wilber DJ. Prospective study of cardiac sarcoid mimicking 
arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol 2009;20:473–476. 
[PubMed: 19017339] 
61. Campbell JP, Turner JE. Debunking the myth of exercise-induced immune suppression: redefining 
the impact of exercise on immunological health across the lifespan. Front Immunol 2018;9:648. 
[PubMed: 29713319] 
62. Campuzano O, Fernandez-Falgueras A, Sarquella-Brugada G, Sanchez O, Cesar S, Mademont I, 
Allegue C, Mates J, Perez-Serra A, Coll M, Alcalde M, Iglesias A, Tiron C, Gallego MA, Ferrer-
Costa C, Hospital A, Escribano C, Dasi C, Borondo JC, Castella J, Arbelo E, Medallo J, Brugada 
J, Brugada R. A genetically vulnerable myocardium may predispose to myocarditis. J Am Coll 
Cardiol 2015;66:2913–2914. [PubMed: 26718681] 
63. van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, van 
Tintelen JP, van den Berg MP, Pilotto A, Pasotti M, Jenkins S, Rowland C, Aslam U, Wilde AA, 
Perrot A, Pankuweit S, Zwinderman AH, Charron P, Pinto YM. Risk factors for malignant 
ventricular arrhythmias in lamin A/C mutation carriers: a European cohort study. J Am Coll 
Cardiol 2012;59:493–500. [PubMed: 22281253] 
64. Akdis D, Saguner AM, Shah K, Wei C, Medeiros-Domingo A, von Eckardstein A, Luscher TF, 
Brunckhorst C, Chen HS, Duru F. Sex hormones affect outcome in arrhythmogenic right 
ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to 
clinical biomarkers of disease outcome. Eur Heart J 2017;38:1498–1508. [PubMed: 28329361] 
65. Hong TT, Cogswell R, James CA, Kang G, Pullinger CR, Malloy MJ, Kane JP, Wojciak J, Calkins 
H, Scheinman MM, Tseng ZH, Ganz P, De Marco T, Judge DP, Shaw RM. Plasma BIN1 correlates 
with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular 
cardiomyopathy. Heart Rhythm 2012;9:961–967. [PubMed: 22300662] 
66. Broch K, Leren IS, Saberniak J, Ueland T, Edvardsen T, Gullestad L, Haugaa KH. Soluble ST2 is 
associated with disease severity in arrhythmogenic right ventricular cardiomyopathy. Biomarkers 
2017;22:367–371. [PubMed: 28067540] 
67. Chatterjee D, Fatah M, Akdis D, Spears DA, Koopmann TT, Mittal K, Rafiq MA, Cattanach BM, 
Zhao Q, Healey JS, Ackerman MJ, Bos JM, Sun Y, Maynes JT, Brunckhorst C, Medeiros-
Domingo A, Duru F, Saguner AM, Hamilton RM. An autoantibody identifies arrhythmogenic right 
ventricular cardiomyopathy and participates in its pathogenesis. Eur Heart J 2018;39:3932–3944. 
[PubMed: 30239670] 
68. Gilotra NA, Bhonsale A, James CA, Te Riele ASJ, Murray B, Tichnell C, Sawant A, Ong CS, 
Judge DP, Russell SD, Calkins H, Tedford RJ. Heart failure is common and under-recognized in 
patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circ Heart Fail 
2017;10:e003819. [PubMed: 28874384] 
69. Mast TP, James CA, Calkins H, Teske AJ, Tichnell C, Murray B, Loh P, Russell SD, Velthuis BK, 
Judge DP, Dooijes D, Tedford RJ, van der Heijden JF, Tandri H, Hauer RN, Abraham TP, 
Doevendans PA, Te Riele AS, Cramer MJ. Evaluation of structural progression in arrhythmogenic 
right ventricular dysplasia/cardiomyopathy. JAMA Cardiol 2017;2:293–302. [PubMed: 28097316] 
70. Sawant AC, Calkins H. Sports in patients with arrhythmogenic right ventricular dysplasia/
cardiomyopathy and desmosomal mutations. Herz 2015;40: 402–409. [PubMed: 25963172] 
71. Sawant AC, Te Riele AS, Tichnell C, Murray B, Bhonsale A, Tandri H, Judge DP, Calkins H, 
James CA. Safety of American Heart Association-recommended minimum exercise for 
desmosomal mutation carriers. Heart Rhythm 2016;13:199–207. [PubMed: 26321091] 
72. Ruwald AC, Marcus F, Estes NA 3rd, Link M, McNitt S, Polonsky B, Calkins H, Towbin JA, Moss 
AJ, Zareba W. Association of competitive and recreational sport participation with cardiac events 
in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North 
American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 
2015;36:1735–1743. [PubMed: 25896080] 
73. Cattin ME, Ferry A, Vignaud A, Mougenot N, Jacquet A, Wahbi K, Bertrand AT, Bonne G. 
Mutation in lamin A/C sensitizes the myocardium to exercise-induced mechanical stress but has no 
effect on skeletal muscles in mouse. Neuromuscul Disord 2016;26:490–499. [PubMed: 27287550] 
Elliott et al. Page 12

















































74. Asimaki A, Kapoor S, Plovie E, Karin Arndt A, Adams E, Liu Z, James CA, Judge DP, Calkins H, 
Churko J, Wu JC, MacRae CA, Kleber AG, Saffitz JE. Identification of a new modulator of the 
intercalated disc in a zebrafish model of arrhythmogenic cardiomyopathy. Sci Transl Med 
2014;6:240ra74.
75. Chelko SP, Asimaki A, Andersen P, Bedja D, Amat-Alarcon N, DeMazumder D, Jasti R, MacRae 
CA, Leber R, Kleber AG, Saffitz JE, Judge DP. Central role for GSK3beta in the pathogenesis of 
arrhythmogenic cardiomyopathy. JCI Insight 2016;1:85923. [PubMed: 27170944] 
76. Muchir A, Wu W, Choi JC, Iwata S, Morrow J, Homma S, Worman HJ. Abnormal p38alpha 
mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene 
mutation. Hum Mol Genet 2012;21: 4325–4333. [PubMed: 22773734] 
Elliott et al. Page 13


















































Ideogram showing current terms that describe different arrhythmogenic cardiomyopathy 
phenotypes and their possible relationship to left (LV) and right ventricular (RV) disease. By 
definition, arrhythmogenic RV cardiomyopathy affects predominantly the right ventricle but 
biventricular forms are frequently seen. Arrhythmogenic dilated cardiomyopathy and left-
dominant arrhythmogenic cardiomyopathy describe overlapping entities that mostly affect 
the left ventricle but RV involvement is also observed. Isolated non-ischaemic scar and 
hypokinetic non-dilated cardiomyopathy mostly refer to predominantly LV scarring 
identified using cardiac magnetic resonance imaging.1–3
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This schematic shows the complex integration of mechanical and electrochemical signalling 
at cardiac intercalated discs and highlights the proposed remodelling of desmosomes, gap 
junctions and ion channels in arrhythmogenic cardiomyopathy. Desmosomes, which are a 
primary target for arrhythmogenic cardiomyopathy-causing mutations, are distributed in 
close proximity with adherens junctions, gap junctions (made of connexins) and sodium 
channels. Both desmosomes and adherens junctions have at their central adhesive core 
members of the cadherin family of calcium-dependent adhesion molecules [desmoglein 2 
(DSG2) and desmocollin 2 (DSC2) in desmosomes, and N-cadherin (N-Cad) in adherens 
junctions]. Linking these molecules to the desmin intermediate filament and actin 
cytoskeletons, respectively, are a complex of armadillo and cytoskeletal linker proteins 
consisting of plakophilin 2 (PKP2), plakoglobin (PG) and the intermediate filament 
anchoring protein desmoplakin (DP) in desmosomes; and beta-catenin (β-Cat), p120 catenin 
and the actin binding protein alpha T-catenin (αT-Cat) in adherens junctions. In the heart, 
alpha-T catenin can interlink with PKP2, providing a structural link between desmosome 
and adherens junctions that results in inter-mixing and stabilizes the cortical cytoskeleton. 
Mixed junctions appearing in vertebrates are called the ‘area composita’. Examples of 
functional interactions at the intercalated discs relevant to arrhythmogenic cardiomyopathy 
are shown. These include DP-dependent trafficking and stabilization of connexin-43 (Cx43) 
and associated gap junction communication through(ia) EB1-dependent microtubule 
stabilization at junctions, and (ii) DP-dependent regulation of Erk1/2-dependent turnover of 
Cx43 through dampening Ras. In addition, distribution and function of the voltage-gated 
sodium channel (VGSC) Nav1.5 depends on PKP2 and its associated adaptor protein ankyrin 
G (AnkG). Conflicting data associate perturbation of Wnt/β-Cat signalling through 
alterations in PG, β-Cat distribution and Hippo signalling (blocks Wnt), with adipogenic vs. 
fibrotic cell fate during arrhythmogenic cardiomyopathy development. Desmosomes can 
themselves be regulated by a combination of the ectodomain sheddase ADAM17 and 
epidermal growth factor receptor (EGFR) signalling [which is itself regulated via the release 
of EGFR ligands, such as EGF-like growth factor (HB-EGF) in cardiac muscle, by 
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ADAM17], which cooperate to regulate cleavage of DSG2. This serves to remodel 
desmosomes and coordinates this remodelling with gene expression changes associated with 
arrhythmogenic cardiomyopathy. PI3K, phosphoinositide 3-kinase; TNFα, tumour necrosis 
factor alpha; TNFR, tumour necrosis factor receptor.
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Myocardial histology from a 31-year-old male competitive athlete who died suddenly as first 
manifestation of arrhythmogenic cardiomyopathy. Autopsy revealed biventricular 
arrhythmogenic cardiomyopathy and evidence of myocardial inflammation: (A) 
subepicardial fibrofatty replacement of the left ventricular free wall (Trichrome stain); (B) 
abnormal cardiomyocytes with dysmorphic nuclei, replacement fibrosis and inflammatory 
infiltrates with myocytolysis (arrow); (C) immunotyping for macrophages (CD68 antibody); 
(D) immunotyping for T lymphocytes (CD3 antibody).
Elliott et al. Page 17


















































Suggested flow chart for the general management of ventricular arrhythmia in 
arrhythmogenic cardiomyopathies. The pathways for management are critically dependent 
on aetiology as well as the clinical profile of individual patients. ICD, implantable 
cardioverter-defibrillator; LV, left ventricular; RV, right ventricular; VA, ventricular 
arrhythmia; VE, ventricular ectopy.
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Table 1




• Consensus on disease nomenclature and definition in AC.
• More precise definition of clinical phenotypes encompassed by the label AC.
• Studies of population incidence and prevalence of genetic mutations and phenotypes including the 
influence of ethnicity.
• Better definitions of pathogenicity for specific genes with emphasis on final common pathways.
• Genome wide association studies and extensive phenotype-genotype correlation studies of families with 
known pathogenic mutations to explore insights into phenotypic variation.
• Investigation of non-coding and epigenetic regulation of genes and post-translational modification of 
proteins associated with AC.
Role of the 
desmosome
• Studies of extracardiac disease, as in the skin, to better define underlying disease mechanisms.
Role of 
inflammation
• Investigation of the characteristics of the AC inflammasome in animal models and in man.
• Determination of the role of myocarditis on disease presentation and prognosis.
Sudden cardiac 
death prediction
• Risk prediction algorithms that quantify risk using easily measurable and repeatable clinical variables for 
specific forms ofAC.
• Evaluation of circulating biomarkers to aid quantification of risk and predict hot phases.
• Optimisation of patient selection for S-ICD vs. transvenous ICD to minimize inappropriate ICD therapies 
and device complications.




• Trials of classical neurohormonal antagonists (BB, ACEi, ARB, ARNI, MRA) with the goal of 
repurposing them for AC.
• Disease-specific pathogenic pathways should be evaluated as potential therapeutic targets.
• Use of the skin and hair as a test bed for drug development.
• Establish endpoints for clinical trials including surrogates that might hasten drug approval.
AC, arrhythmogenic cardiomyopathy; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin 
receptor–neprilysin inhibitor; BB, beta-blocker; ICD, implantable cardioverter-defibrillator; MRA, mineralocorticoid receptor antagonist; S-ICD, 
subcutaneous implantable cardioverter-defibrillator.
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Table 2
Observed phenotypes associated with mutations in arrhythmogenic cardiomyopathy-related genes
Gene Predominant RV disease Biventricular disease Predominant LV disease Other characteristics Ref.
JUP + + − Cardiocutaneous syndrome 4
DSP − + + Cardiocutaneous syndrome 25
PKP2 + + − 6,26
DSG2 + + + 8,26
DSC2 + + − 9,26
TGFB3 + Unknown Unknown 27
TMEM43 + + − 28
TTN + + + 19,29
DES − + + 10
Lamin A/C − + + Conduction disease 11
PLN − + + 16,26
CTNNA3 + + − 14
CDH2 + + − 13
SCN5A − + + Electrical > structural disease 1 2,29
FLNC − + + 15
RBM20 Unknown Unknown + 30
BAG3 Unknown Unknown + 31
A literature review identified the spectrum of phenotypes in relation to ventricular disease in patients with carrying mutations in AC-related genes. 
Presence of disease is marked with ‘+’ and absence with ‘−’.
BAG3, Bcl2-associated athanogene 3; CDH2, cadherin 2; CTTNA3, catenin alpha 3; DES, desmin; DSC2, desmocolin 2; DSG2, desmoglein 2; 
DSP, desmoplakin; FLNC, filamin C; JUP, plakoglobin; LV, left ventricular; PKP2, plakophillin 2; PLN, phospholamban; RBM20, RNA binding 
motif protein 20; RV, right ventricular; SCN5A, sodium voltage-gated channel alpha subunit 5; TGFB3, transforming growth factor beta 3; 
TMEM43, transmembrane protein 43; TTN, titin.
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